First Wave BioPharma engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Co. is focused on developing its drug product candidate, MS1819, a yeast derived recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. Co.'s b-lactamase program focuses on products with an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea by resistant bacterial strains induced by parenteral administration of several antibiotic classes. Co.'s compounds in pre-clinical development include: AZX1101 and AZX1103. The FWBI stock yearly return is shown above.
The yearly return on the FWBI stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FWBI annual return calculation with any dividends reinvested as applicable (on ex-dates).
|